ABSTRACT
Indigenous people worldwide are at high-risk of developing severe influenza disease. HLA-A*24:02 allele, highly prevalent in Indigenous populations, is associated with influenza-induced mortality, although the basis for this association is unclear. We defined CD8+ T-cell immune landscapes against influenza A (IAV) and B (IBV) viruses in HLA-A*24:02-expressing Indigenous and non-Indigenous individuals, human tissues, influenza-infected patients and HLA-A*24:02-transgenic mice. We identified immunodominant protective CD8+ T-cell epitopes, one towards IAV and six towards IBV, with A24/PB2550-558-specific CD8+ T-cells cells being cross-reactive between IAV and IBV. Memory CD8+ T-cells towards these specificities were present in blood (CD27+CD45RA- phenotype) and tissues (CD103+CD69+ phenotype) of healthy subjects, and effector CD27-CD45RA-PD-1+CD38+CD8+ T-cells in IAV/IBV patients. Our data present the first evidence of influenza-specific CD8+ T-cell responses in Indigenous Australians, and advocate for T-cell-mediated vaccines that target and boost the breadth of IAV/IBV-specific CD8+ T-cells to protect high-risk HLA-A*24:02-expressing Indigenous and non-Indigenous populations from severe influenza disease.
One Sentence Summary Influenza-specific CD8+ T-cell specificities restricted by HLA-A*24:02.
Competing Interest Statement
SR is an employee of Seqirus Ltd and has no conflict of interest in the material presented. LH, EBC, MK and KK are named as co-inventors in a patent application filed by the University of Melbourne (PCT/AU2018/050971) covering the use of certain peptides described in the publication as part of vaccine formulation. The other authors declare no conflicts of interest.
Funding Statement
The Australian National Health and Medical Research Council (NHMRC) Program Grant (1071916) to KK, NHMRC Project Grant (1122524) to KK, ST, AM, SG and AWP, and NHMRC Investigator Grant (1173871) to KK supported this work. LH was a recipient of Melbourne International Research Scholarship and Melbourne International Fee Remission Scholarship. CES had received funding from the European Union Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement (792532). JR is supported by an ARC Laureate fellowship. SG is a NHMRC SRF-A Fellow (1159272). EBC is NHMRC Peter Doherty Fellow. AWP is supported by an NHMRC Principal Research Fellowship (1137739) and NHMRC Project grant (1085018) to AWP, NAM and TCK. ST is a NHMRC Career Development Fellow (1145033). EJG is and NHMRC CJ Martin Fellow.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Human experimental work was conducted according to the Declaration of Helsinki Principles and according to the Australian National Health and Medical Research Council Code of Practice. All blood and tonsil donors provided written consent prior to study participation. Lung tissues, lymph node and spleen samples were obtained from deceased organ donors after receiving written informed consent from next-of-kin. Lungs were sourced from the Alfred Hospital's Lung Tissue Biobank. Lymph node and spleen were provided by DonateLife Victoria. Buffy packs were sourced from the Australian Red Cross Lifeblood (West Melbourne, Australia). Human experimental work was approved by the University of Melbourne Human Ethics Committee (ID 1955465.2, 1443389.4, 1441452.1 and 1954302.1), the Australian Red Cross Lifeblood Ethics Committee (ID 2015 number 8), the Alfred Hospital Ethics Committee (ID 280/14), Monash Health Human Research Ethics Committee (HREC) (ID HREC/15/MonH/64, RMH local reference number 2016/196), HREC of Northern Territory Department of Health and Menzies School of Health Research (ID 2012-1928) and Tasmanian Health and Medical HREC (ID H0017479). Human PBMCs and cells from tissues were isolated and cryopreserved as previously described70. Indigenous donors (LIFT) were recruited as described before.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are available upon request.
